8-KEarnings & ResultsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Oct 21, 2004)

Filed October 21, 2004For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on October 21, 2004, to report its third-quarter financial results ended September 30, 2004, as announced in a press release issued that same day. The filing primarily serves to furnish the earnings press release as an exhibit and to provide context for the financial information presented. Gilead management utilizes non-GAAP financial measures to assess ongoing results, excluding specific items deemed unusual due to their nature, size, or infrequency.

Key Highlights

  • 1Gilead Sciences announced its third-quarter 2004 financial results on October 21, 2004.
  • 2The 8-K filing primarily incorporates an earnings press release (Exhibit 99.1) detailing these results.
  • 3The company uses non-GAAP financial measures to provide insights into core business performance, excluding unusual items.
  • 4Specific unusual items mentioned include a fair value gain on EyeTech Pharmaceuticals warrants, an in-process R&D charge from the Triangle Pharmaceuticals acquisition, and a vendor settlement payment.
  • 5Management believes these non-GAAP measures offer a clearer view of trends affecting the core business for both management and investors.
  • 6John F. Milligan, Executive Vice President and Chief Financial Officer, signed the report.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report and furnish Gilead Sciences' earnings press release for the third quarter ended September 30, 2004. It serves as an official record of the company's financial results announcement.

Gilead uses non-GAAP financial measures because management believes they provide a more useful understanding of the company's ongoing operational results and trends by excluding certain transactions that are considered unusual due to their nature, size, and infrequency. This allows for a clearer view of the core business performance.

The filing specifically mentions a fair value gain on EyeTech Pharmaceuticals warrants (due to EyeTech's IPO), an in-process research and development charge from the Triangle Pharmaceuticals acquisition, and a settlement payment from a contractual dispute with a vendor.

The third-quarter 2004 results were announced and reported in a press release issued by Gilead Sciences on October 21, 2004.